总之，肥胖、糖尿病、酒精滥用及其所致肝脂肪变不但是FLD的重要原因，而且可影响慢性病毒性肝炎等其他肝病的发生、发展以及治疗转归。戒酒、减肥、改善IR不但可以有效防治FLD而且有可能改变慢性病毒性肝炎的自然史，从而最大程度地改善肝病患者的预后。目前国外对病毒性肝炎与FLD相互关联的研究主要集中于CHC，对嗜酒、代谢紊乱、FLD与CHB相互关系的研究仅有零星报道；国内相关研究则更少。为此，有必要加强病毒性肝炎合并脂肪肝的基础和临床研究，争取在不久的将来能够率先在我国成立“病毒性肝炎合并脂肪肝临床病理研究协作组”并制定相关诊疗指南以指导临床实践。
参 考 文 献
1. Williams R. Global changes in liver disease. Hepatology，2006，44:521-526.
2. Taylor BC， Yuan JM， Shamliyan TA，et al. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence. Hepatology. 2009，49:S85-95.
3. Cheung O，Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis. 2008，12:573-85.
4. Fan JG，Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol，2008，23:779-782.
5. Cross TJ，Quaglia A，Hughes S，et al. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009，16:492-9.
6. Fan JG，Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009，50:204-10.
7. Shi J，Fan JG，Wu R，et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008，23:1419-1425.
8. Petta S，Cammà C，Marco VD，et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol.2008，103:1136-44.
9. Tsochatzis E，Papatheodoridis GV，Hadziyannis E，et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008; 43: 1128-36.
10. Jonsson JR，Barrie HD，O’Rourke P，et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology. 2008，48:80-7.
11. Machado MV，Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. Ann Hepatol.2009，8:S67-75.
12. Wong GL，Wong VW，Choi PC，et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut.2009，58:111-7.
13. Na TY，Shin YK，Roh KJ，et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2009，49:1122-31.
14. Yu MW，Shih WL，Lin CL，et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008，26:5576-82.
15. Targher G，Bertolini L，Padovani R，et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007，46:1126-32.
16. Rodriguez-Torres M，Govindarajan S，Diago M，et al. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. Liver Int. 2009，29:237-41.
